Paper · 41348890
Steric disruption of EGFR oligomerization overcomes therapy resistance in non-small cell lung cancer.
Song D and 3 others. Sci Adv, 2025. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Steric disruption of EGFR oligomerization overcomes therapy resistance in non-small cell lung cancer. Papers, record 41348890. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41348890
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| ErbB Receptors | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Lung Neoplasms | Major topic |
| Protein Multimerization | Major topic |
| Humans | |
| Protein Kinase Inhibitors | |
| Mutation | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Signal Transduction |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R21 GM132687 | NIGMS NIH HHS | United States | R21GM132687 | PubMed and NIH |
Source NIH RePORTER
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36,344,833 | Chemically stable fluorescent proteins for advanced microscopy. | Nat Methods | 2022 | https://conductscience.org/library/papers/36344833 | PubMed |
| 2 | 22,452,895 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. | Lancet Oncol | 2012 | https://conductscience.org/library/papers/22452895 | PubMed |
| 3 | 24,063,894 | Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. | Cancer Res | 2013 | https://conductscience.org/library/papers/24063894 | PubMed |
| 4 | 37,350,862 | Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review. | RSC Adv | 2023 | https://conductscience.org/library/papers/37350862 | PubMed |
| 5 | 25,985,220 | The Dual Characteristics of Light-Induced Cryptochrome 2, Homo-oligomerization and Heterodimerization, for Optogenetic Manipulation in Mammalian Cells. | ACS Synth Biol | 2015 | https://conductscience.org/library/papers/25985220 | PubMed |
| 6 | 2,590,944 | Structure of the Drosophila BicaudalD protein and its role in localizing the posterior determinant nanos. | Cell | 1989 | https://conductscience.org/library/papers/2590944 | PubMed |
| 7 | 23,959,269 | Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. | Nat Rev Clin Oncol | 2013 | https://conductscience.org/library/papers/23959269 | PubMed |
| 8 | 26,609,494 | EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). | Am J Cancer Res | 2015 | https://conductscience.org/library/papers/26609494 | PubMed |
| 9 | 27,017,828 | Molecular basis for multimerization in the activation of the epidermal growth factor receptor. | Elife | 2016 | https://conductscience.org/library/papers/27017828 | PubMed |
| 10 | 24,019,492 | Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/24019492 | PubMed |
1 to 10 of 54
See all 54 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,882,712 | MicroRNA-regulated signaling and tumor microenvironment modulation in lung cancer: mechanistic insights and translational opportunities. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/41882712 | PubMed |
| 41,690,169 | Optimization of ultrasound-assisted extraction of Sargassum polycystum for antitumor activity: Multi-objective optimization and mechanistic insights. | Ultrason Sonochem | 2026 | https://conductscience.org/library/papers/41690169 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGF | 1,950 | PubTator's text mining | https://conductscience.org/library/genes/1950 | NCBI Gene |
| EGFR | 1,956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41348890
GET https://conductscience.org/api/papers/v1/41348890/references?page=2